Last Updated : April 11, 2025
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
dabrafenib-trametinib (TBC)
Therapeutic Area: Pediatric low grade glioma (ped LGG)
Draft recommendations posted for stakeholder feedback: April 11, 2025
End of feedback period: April 29, 2025
Draft Recommendation
Draft Responses to the Questions from the Drug Programs
Draft Clinical & Pharmacoeconomic Combined Report
Draft Combined Report Supplemental Material
regorafenib (N/A)
Therapeutic Area: Metastatic osteosarcoma
Draft recommendations posted for stakeholder feedback: April 11, 2025
End of feedback period: April 29, 2025
Draft Recommendation
Draft Responses to the Questions from the Drug Programs
Draft Clinical & Pharmacoeconomic Combined Report
Draft Combined Report Supplemental Material
Dabrafenib trametinib(N/A)
Therapeutic Area: Head and neck cancer
Draft recommendations posted for stakeholder feedback: April 11, 2025
End of feedback period: April 29, 2025
Draft Recommendation
Draft Responses to the Questions from the Drug Programs
Draft Clinical & Pharmacoeconomic Combined Report
Draft Combined Report Supplemental Material
blinatumomab (Blincyto)
Therapeutic Area: B-cell precursor acute lymphoblastic leukemia
Draft recommendations posted for stakeholder feedback: April 3, 2025
End of feedback period: April 17, 2025
Draft Recommendation
durvalumab, carboplatin, paclitaxel (Imfinzi )
Therapeutic Area: Endometrial cancer that is mismatch repair deficient (dMMR)
Draft recommendations posted for stakeholder feedback: April 3, 2025
End of feedback period: April 17, 2025
Draft Recommendation
daratumumab (Darzalex SC)
Therapeutic Area: Multiple myeloma, eligible for autologous stem cell transplant
Draft recommendations posted for stakeholder feedback: April 3, 2025
End of feedback period: April 17, 2025
Draft Recommendation
pemigatinib (Pemazyre)
Therapeutic Area: Cholangiocarcinoma
Draft recommendations posted for stakeholder feedback: April 3, 2025
End of feedback period: April 17, 2025
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area :
Unresectable or advanced hepatocellular carcinoma (HCC)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
atopic dermatitis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
HER2-low or HER2-ultralow breast cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Giant cell arteritis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Immunoglobulin G4-related disease
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Astrocytoma or oligodendroglioma; IDH1 or IDH2 mutation
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Metastatic castration-sensitive prostate cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Depression
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Attention Deficit Hyperactivity Disorder (ADHD)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :